From Division of Cardiology, Southern Illinois University School of Medicine, Springfield, IL (AK); Community & Family Medicine, Southern Illinois University School of Medicine, Springfield (MM).
J Am Board Fam Med. 2018 Sep-Oct;31(5):817-827. doi: 10.3122/jabfm.2018.05.180007.
With increasing physician and patient awareness, the use of direct oral anticoagulants (DOACs) has been steadily increasing in recent years. Unfortunately, given their recent introduction, the reversal of anticoagulation attained with DOACs is not well studied. Given the diverse mechanisms of action of these newer agents, no universal antidote is available for reversal. Laboratory assays that can accurately quantify the anticoagulation status of patients on DOAC therapy are not readily available, which presents a challenge in situations demanding rapid reversal. Furthermore, the safety and efficacy of reversal agents have not been extensively investigated in the clinical setting.This review briefly summarizes commercially available DOACs, delineates current knowledge related to reversal of DOAC agents in specific clinical settings, and identifies areas of future study.
随着医生和患者意识的提高,近年来直接口服抗凝剂(DOAC)的使用稳步增加。不幸的是,鉴于它们的新近推出,用 DOAC 达到的抗凝逆转尚未得到很好的研究。鉴于这些新型药物作用机制的多样性,没有通用的解毒剂可用于逆转。目前还没有能够准确量化接受 DOAC 治疗的患者抗凝状态的实验室检测方法,这在需要快速逆转的情况下带来了挑战。此外,逆转剂的安全性和有效性尚未在临床环境中得到广泛研究。
本篇综述简要总结了市售的 DOAC,阐述了目前在特定临床情况下与 DOAC 逆转剂相关的知识,并确定了未来研究的领域。